REG - Centrica PLC - Commencement of Share Buyback

CentricaAnnouncement

04/03/2024 18:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240304:nRSD5396Fa&default-theme=true

RNS Number : 5396F  Centrica PLC  04 March 2024

 

Centrica plc

 

 

Commencement of next tranche of share buyback

 

In line with the capital allocation framework laid out in July 2023, and as
part of its ongoing commitment to return surplus capital to shareholders,
Centrica plc (the "Company") announces the commencement of the next £250
million tranche of its £1 billion share repurchase programme.

 

Since 15 November 2022 the Company has repurchased approximately £750 million
of its ordinary shares. Execution of the tranche announced today (the "Second
Tranche") of the £450 million share repurchase programme extension (the
"2023-2024 Programme"), which was announced on 27 July 2023, will take the
total amount of ordinary shares repurchased to approximately £1 billion.

 

For the Second Tranche, the Company has entered into an irrevocable
arrangement with BNP Paribas Financial Markets S.N.C. ("BNP Paribas") (acting
as riskless principal) to conduct the repurchases in respect of the Second
Tranche on its behalf and to make trading decisions in respect of the Second
Tranche independently of the Company.

 

The arrangement with BNP Paribas enables the purchase of ordinary shares for a
period from 5 March 2024 up to and including 31 July 2024. The aggregate
maximum consideration for the purchase of ordinary shares under the Second
Tranche is £250 million (exclusive of associated fees, expenses and stamp
duty), representing an amount equal to the aggregate value of approximately
3.7% of the Company's issued share capital at the closing share price on 4
March 2024. BNP Paribas may effect purchases of shares under the Second
Tranche on the London Stock Exchange and/or other trading venues for
subsequent purchase by the Company. Purchases by the Company will be treated
as being made on the London Stock Exchange. The Company intends that any
shares purchased will be (i) cancelled; or (ii) held in treasury pending
their cancellation.

 

The purpose of the 2023-2024 Programme is to reduce the capital of the
Company.

 

Any share purchase will be carried out in accordance with certain pre-set
parameters. The maximum number of ordinary shares which may be purchased by
the Company under the Second Tranche is 430,630,570, which is the maximum
pursuant to the authority granted by shareholders at the Company's 2023 Annual
General Meeting less the number of shares repurchased in the first £200
million tranche (the "First Tranche") of the 2023-24 Programme, which
commenced on 10 October 2023 and completed on 1 March 2024.

 

The Second Tranche will be conducted within the parameters prescribed by the
Market Abuse Regulation 596/2014/EU (as in force in the UK and as amended by
the Market Abuse (Amendment) (EU Exit) Regulations 2019), the Commission
Delegated Regulation 2016/1052/EU (as in force in the UK and as amended by the
FCA's Technical Standards (Market Abuse Regulation) (EU Exit) Instrument 2019)
and in accordance with Chapter 12 of the UK Listing Rules. No repurchases will
be made in respect of the Company's American Depositary Receipts.

 

The Company will make further announcements in due course following any
repurchase of shares. There is no guarantee that the Second Tranche will be
implemented in full or that any shares will be bought back by the Company.

 

Enquiries:

Investors and Analysts

T: 01753 494900

E: ir@centrica.com

 

Media

T: 01784 843000

E: media@centrica.com

 

 

END

 

Centrica plc is listed on the London Stock Exchange (CNA)

Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654

Legal Entity Identifier number: E26EDV109X6EEPBKVH76

ISIN number:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSUSAWRSWUORAR